In This Section

AACR Project GENIE: Participation

Project GENIE’s approach to data harmonization is such that each participating organization can continue to operate how it best sees fit while simultaneously contributing its data to the project. AACR Project GENIE Participating Institutions include many of the world’s vanguard academic centers with expertise in genomics, molecular pathology, cancer biology, clinical trial design/execution, and medical informatics.

Consortium Participants

  • Cancer Research UK Cambridge Centre, University of Cambridge, Cambridge, England
  • Children’s Hospital of Philadelphia Cancer Center, Philadelphia, Pennsylvania
  • Dana-Farber Cancer Institute, Boston, Massachusetts*
  • Duke University (Duke Cancer Institute), Durham, North Carolina
  • Gustave Roussy Cancer Campus, Paris-Villejuif, France*
  • Herbert Irving Comprehensive Cancer Center, Columbia University, New York, New York
  • The Netherlands Cancer Institute, Amsterdam, on behalf of the Center for Personalized Cancer Treatment, Utrecht, The Netherlands*
  • Memorial Sloan Kettering Cancer Center, New York*
  • Princess Margaret Cancer Centre, Toronto, Ontario, Canada*
  • Providence Cancer Institute, Portland, Oregon
  • Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland*
  • Swedish Cancer Institute, Seattle, Washington
  • University of California-San Francisco (UCSF Helen Diller Family Comprehensive Cancer Center), San Francisco, California
  • The University of Chicago Comprehensive Cancer Center, Chicago, Illinois
  • Vanderbilt-Ingram Cancer Center, Nashville, Tennessee*
  • Vall d’ Hebron Institute of Oncology, Barcelona, Spain
  • Wake Forest University Health Sciences (Wake Forest Baptist Medical Center), Winston-Salem, North Carolina
  • Yale University (Yale Cancer Center), New Haven, Connecticut

Participating Institutions REquirements

  • Provide 500 genomic records to start; 500 each subsequent year of participation: Data must be CLIA- or ISO-certified
  • Limited Data sets as defined by 45 C.F.R. § 164.514(e) will be provided
  • If de-identified datasets are provided, the process must adhere to the project’s established protocol
  • Maintain IRB approval
  • Meet data standards and deadlines
  • Participate in meetings
  • Participate in committees and subcommittees
  • Execute the Master Participation Agreement and agree to all exhibits, including the Data User Agreement
  • Past GENIE new participant applicants were judged based on these criteria: AACR Project GENIE Participation Evaluation Criteria

Informatics Partners

  • Sage Bionetworks, Seattle, Washington
  • cBioPortal, New York, New York

Criteria for Informatics Strategic Partners

  • Significant prior experience in similar projects
  • Secure, HIPAA-compliant infrastructure
  • Established and accepted platforms
  • Significant bioinformatics expertise

New Participating Institutions

  • The open call for new participating institutions will begin on May 1st, 2022. Find more information about the 2022 GENIE New Participant Open call here.